54765-26-3

Basic information

• Product Name: 4,5-Dihydro-2-[(2,4,6-trimethylphenyl)methyl]-1H-imidazole
• Synonyms: 4,5-Dihydro-2-[(2,4,6-trimethylphenyl)methyl]-1H-imidazole
• CAS NO: 54765-26-3
• Molecular Formula: C₁₃H₁₈N₂
• Molecular Weight: 202.3
• Mol File: 54765-26-3.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4,5-Dihydro-2-[(2,4,6-trimethylphenyl)methyl]-1H-imidazole(CAS DataBase Reference)
• NIST Chemistry Reference: 4,5-Dihydro-2-[(2,4,6-trimethylphenyl)methyl]-1H-imidazole(54765-26-3)
• EPA Substance Registry System: 4,5-Dihydro-2-[(2,4,6-trimethylphenyl)methyl]-1H-imidazole(54765-26-3)

Safety Data

• Hazardous Substances Data: 54765-26-3(Hazardous Substances Data)

Upstream product

• 4761-00-6 2,4,6-trimethylbenzylbromide 
• 34688-71-6 mesitylacetonitrile 

Relevant articles and documents

Method for the treatment of CNS disorders with substituted 2-imidazoles or imidazole derivatives

The present invention relates a method for treating depression, anxiety disorders, bipolar disorder, attention deficit hyperactivity disorder, stress-related disorders, psychotic disorders such as schizophrenia, neurological diseases such as Parkinson's disease, neurodegenerative disorders such as Alzheimer's disease, epilepsy, migraine, hypertension, substance abuse and metabolic disorders such as eating disorders, diabetes, diabetic complications, obesity, dyslipidemia, disorders of energy consumption and assimilation, disorders and malfunction of body temperature homeostasis, disorders of sleep and circadian rhythm, and cardiovascular disorders which comprises administering to an individual a therapeutically effective amount of a compound of formula I wherein R, R1, R2, A and n are as defined in the specification and to their pharmaceutically active salts. The invention also relates to novel compounds of formula I, pharmaceutical compositions containing them, and methods for their preparation.

Benzylimidazolines as h5-HT(1B/1D) serotonin receptor ligands: A structure-affinity investigation

Benzylimidazolines may represent a class of 5-HT(1D) ligands that has yet to be exploited. On the basis of a previous report that the 2- (substituted-benzyl)imidazoline α-adrenergic agonist oxymetazoline (8) binds with high affinity at calf brain 5-HT(1D) receptors, we explored the structure-affinity relationships of a series of related derivatives. Each of the aromatic substituents was removed and then reinstated in a systematic manner to determine the influence of the individual substituents on binding. It was found that all of the aromatic substituents of 8 act in concert to impart high affinity. However, although the 3-hydroxy group could be removed without significantly reducing affinity for h5-HT(1D) (i.e., human 5- HT(1Dα)) receptors, this modification reduced h5-HT(1B) (i.e., human 5- HT(1Dβ)) receptor affinity by nearly 50-fold. The 2,6-dimethyl groups also contribute to binding but seem to play a greater role for h5-HT(1B) binding than h5-HT(1D) binding. With the appropriate structural modifications, several compounds were identified that display 20- to > 100-fold selectivity for h5-HT(1D) versus h5-HT(1B) receptors. Preliminary functional data suggest that these compounds behave as agonists. Given that 5-HT(1D) agonists are currently being explored for their antimigraine action and that activation of h5-HT(1B) receptors might be associated with cardiovascular side effects, h5- HT(1D)selective agents may offer a new lead for the development of therapeutically efficacious agents.